Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
about
Transcriptional regulation of apolipoprotein C-III gene expression by the orphan nuclear receptor RORalphaMetabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteinsThe crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemiaStructure and dynamics of human apolipoprotein CIIIWhy Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?Apoprotein C-III deficiency markedly stimulates triglyceride secretion in vivo: comparison with apoprotein EAlterations in hepatic metabolism in fld mice reveal a role for lipin 1 in regulating VLDL-triacylglyceride secretion.Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes.Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteinsOrphan nuclear hormone receptor Rev-erbalpha regulates the human apolipoprotein CIII promoter.A rare variant in APOC3 is associated with plasma triglyceride and VLDL levels in Europeans.Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.Complex interplay between the lipin 1 and the hepatocyte nuclear factor 4 α (HNF4α) pathways to regulate liver lipid metabolismApolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistanceBexarotene: a clinical review.Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan.ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiencyApolipoprotein polymorphisms and familial hypercholesterolemia.Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic miceApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.Influence of apolipoproteins on the association between lipids and insulin sensitivity: a cross-sectional analysis of the RISC Study.Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets.Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.The genetics of familial combined hyperlipidaemia.Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity.Experimental Biology for the Identification of Causal Pathways in Atherosclerosis.ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans.ApoC-III gene expression is sharply increased during adipogenesis and is augmented by retinoid X receptor (RXR) agonists.Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP.Overexpression of apoC-III produces lesser hypertriglyceridemia in apoB-48-only gene-targeted mice than in apoB-100-only mice.Apolipoprotein C-III inhibits triglyceride hydrolysis by GPIHBP1-bound LPL.ApoC-III deficiency prevents hyperlipidemia induced by apoE overexpression.Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII.Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism.
P2860
Q24290442-9156A4E2-009E-4CD2-BE85-8EF55B717C3EQ24651503-84984258-9E7E-41BA-9334-E7A71703F417Q26864682-D4BF217E-F612-4D22-BEB5-64DFE29E9AB7Q27650312-B968F240-0DAB-4B69-9458-097B8B326140Q28077776-761687F9-A25D-4BF4-BBEA-94F59FA4C474Q28508473-7E31A3C9-60AF-4F3A-9AD3-886DA9296FDCQ30439917-40F3D7B8-C413-4A11-AF3F-A14EE9A54B0BQ33962626-68F18FD0-0E5F-4A53-A4D8-64E27C2969DEQ34013800-3F2BE35F-3144-4673-81D9-E042E01AF230Q34129395-3E1783EA-83A3-4981-B2B5-1C13E206284FQ34205523-F921307D-6EB5-46A0-94B6-BF468BF1A406Q34480492-0B136F57-88EE-4AA7-9CF3-36338FACCE02Q34510859-3159EDC1-2832-4AE8-BDD4-2A9F4808173FQ35489364-BF01CB8B-5439-4FCB-BC60-5893951EF6FFQ35728639-DB8F19C6-8B59-4C87-82A7-3FDE1CA7A6CDQ35923466-E81040F2-6065-4F68-AEBF-E852BC747AFDQ36527075-BEA90D49-0D4F-4361-9EC5-EA291D41B813Q36558367-A68D574D-67E7-4EF4-A30D-CBDCE53B72BDQ36966031-E5D3AF9F-A970-454E-9F11-B7C749706EBBQ37078689-97B79E20-1803-481B-91AC-B11C04904609Q37202057-7144BCFB-1405-4918-A3CB-A425AC4728C3Q37317424-2CA8A6F4-2801-4B83-898A-8E5A35F173EEQ37331224-A4D3F823-4367-4109-A13E-F0F8D5A635E8Q37333795-CA78F327-818A-4D7D-8969-70D94C5BDB6CQ37384407-8A60307A-566C-4D31-9CA2-0746F29FA035Q37444625-01513C79-81D0-4A70-9C82-78AD4031DFAAQ37456662-1199AB59-BDEF-4C2B-9AF8-5EBD85BECD89Q37983699-4DD20C10-0170-4A56-AAEE-1B34B5C8DF6DQ38682093-BD0201E5-5E03-4726-902E-D363BDFCF415Q38723704-C74E0D35-9E1C-4F17-B78E-829E2A7DDF0AQ39614082-35F4E906-F235-40D2-AC5A-8C252A066F8BQ41916623-9FE9082B-FA07-45B6-9E41-47B84DE6E81EQ42804566-16E9F761-B3F0-4318-918D-CA0BDE0A578DQ44231224-FDDB8D19-A2EE-474D-B9F9-806F97402CB7Q44854865-1C5C3BD4-43CE-40CA-8EC0-A64619C40D83Q45041090-AF0AB650-ED54-436F-BBA9-36C5844B9360Q46300109-058D7363-94C8-4B29-ADB3-1F811C49752BQ46466019-7CAA6ADD-D644-460A-9631-409CF314829BQ46702771-1ADBE086-269A-449B-8C9B-CD1DFD1BD799Q46958396-AE950D4A-CDA8-4040-AF9C-C512410784B0
P2860
Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 1997
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chylomicronemia due to apolipo ...... by effects on apolipoprotein E
@en
Chylomicronemia due to apolipo ...... y effects on apolipoprotein E.
@nl
type
label
Chylomicronemia due to apolipo ...... by effects on apolipoprotein E
@en
Chylomicronemia due to apolipo ...... y effects on apolipoprotein E.
@nl
prefLabel
Chylomicronemia due to apolipo ...... by effects on apolipoprotein E
@en
Chylomicronemia due to apolipo ...... y effects on apolipoprotein E.
@nl
P2093
P2860
P356
P1476
Chylomicronemia due to apolipo ...... by effects on apolipoprotein E
@en
P2093
Ramakrishnan R
Shachter NS
P2860
P304
P356
10.1172/JCI119456
P407
P577
1997-06-01T00:00:00Z